# The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib

> **NCT03528941** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 109 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Lamivudine
- **OTHER:** No prophylaxis

## Key facts

- **NCT ID:** NCT03528941
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-28
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-06-30
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2022-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03528941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03528941, "The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03528941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*